Organisation paid for research Program year 2025 Source: CMS Open Payments

Celerion, Inc.

Neither a doctor nor a teaching hospital

Research payments

$16,973,649

261 payments

Through program year 2025, Celerion, Inc. is reported as receiving $16,973,649 in research payments, across 261 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $1,460,641 3
2023 Research $137,663 8
2022 Research $4,722,677 36
2021 Research $5,934,944 44
2020 Research $4,036,308 135
2019 Research $681,416 35

Breakdown

Who paid Research payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $5,543,262 156 payments
  2. Retrophin, Inc. $4,977,788 39 payments
  3. Neurocrine Biosciences, Inc. $4,038,246 26 payments
  4. Taiho Oncology, Inc. $2,356,820 38 payments
  5. Jazz Pharmaceuticals Inc. $57,533 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. Rtrx-Re021-101 $2,008,087 9 payments
  2. A Phase 1, Single-Dose, Randomized, Placebo- and Active-Controlled, Four-Way, Cross Over Study for the Evaluation of the Effect of Crinecerfont on the QT/QTc Intervals in Adult Healthy Subjects $1,990,203 7 payments
  3. A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral MK-8591 Once-Monthly in Participants at Low-Risk for HIV-1 Infection $1,586,112 37 payments
  4. Phase 1, Randomized, Open-Label Study in Heathy Adult Subjects to Evaluate the the Bioequivalence of Softgel and Hardgel Crinecerfont Capsules and the Effect of Food on Bioavailability $1,584,997 7 payments
  5. An Open-Label, Phase 1 Study to Characterize the Effects of Phenytoin on the Pharmacokinetics of Belzutifan in Healthy Adult Participants $1,416,120 1 payment
  6. Tvtx-Cholb-101 $991,579 5 payments
  7. Tas-120-107 $903,401 7 payments
  8. Rtrx-Re021-103 $899,074 7 payments
  9. A Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Islatravir MK-8591 on the QTc Interval in Healthy Adult Participants $748,797 1 payment
  10. An Open-Label Trial to Assess the Effect of Multiple Doses of Rifabutin on the Single-Dose Pharmacokinetics of MK-8507 in Healthy Adult Participants. $681,330 2 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $4,977,788 39 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record